clinical trial · NCT07638891
A Study of HDM2020 in Patients With Advanced Sq-NSCLC
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·phase1·recruiting·n = 150
Squamous Non-small Cell Lung Cancer(NSCLC)HDM2020 (FGFR2b-ADC)
brief summary
The goal of this clinical trial is to learn if the study drug can treat in advanced squamous non-small cell lung cancer(NSCLC) patients. The main questions it aims to answer are: Is the drug safe and tolerable? Does the drug show antitumor activity? Participants will receive the study drug once(D1) or twice(D1.D8) every three weeks, and undergo imaging-based efficacy assessments every six weeks.
started
Apr 1, 2026
primary completion
Jan 31, 2027
completion
Nov 3, 2027
last updated
Jun 10, 2026
detailed description
Target population are patients with FGFR2-expressing late line squamous non-small cell lung cancer(NSCLC) tumors.
official title
A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of HDM2020 in Patients With Advanced Squamous Non-small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol